SCHEMBL1992866

SCHEMBL1992866

Brc1cnc2cc(C3=CC=C3)nn2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 6/20 0.42
ALDH1A1 P00352 4/20 0.42
GAA P10253 2/20 0.42
MAPT P10636 2/20 0.42
ESR2 Q92731 4/20 0.40
HPGD P15428 2/20 0.40
TSHR P16473 1/20 0.40
POLB P06746 7/20 0.39
KDM4E B2RXH2 5/20 0.39
HSD17B10 Q99714 3/20 0.39
RAB9A P51151 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
APOBEC3A P31941 2/20 0.39
APOBEC3G Q9HC16 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
RECQL P46063 1/20 0.39
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
NR4A1 P22736 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5057039 0.77 RAB9A (0.49) TDP1ALDH1A1GAAMAPTESR2
SCHEMBL1996955 0.74 GRM5 (0.38) MAPTKDM4ERAB9ASMN1; SMN2RXFP1
SCHEMBL9903581 0.73 AHR (0.50) TDP1ALDH1A1GAAMAPTESR2
SCHEMBL974117 0.70 RAB9A (0.56) TDP1ALDH1A1GAAMAPTESR2
SCHEMBL18555435 0.70 TDP1 (0.47) TDP1ALDH1A1GAAMAPTESR2
SCHEMBL22027717 0.70 TDP1 (0.47) TDP1ALDH1A1GAAMAPTESR2
SCHEMBL2749067 0.70 FYN (0.46) TDP1ALDH1A1GAAMAPTHPGD
SCHEMBL1011158 0.69 TDP1 (0.63) TDP1ALDH1A1GAAMAPTESR2
SCHEMBL2749656 0.69 ALDH1A1 (0.46) TDP1ALDH1A1GAAMAPTESR2
SCHEMBL21752181 0.68 TDP1 (0.51) TDP1ALDH1A1GAAMAPTESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2513102-B1 ETHYNYL DERIVATIVES HOFFMANN LA ROCHE (CH) 2015-08-19 EP disclosed
US-8933094-B2 Ethynyl compounds useful for treatment of CNS disorder HOFFMANN-LA ROCHE INC. (US) 2015-01-13 US disclosed
US-20140073638-A1 ETHYNYL COMPOUNDS USEFUL FOR TREATMENT OF CNS DISORDER HOFFMANN-LA ROCHE INC. (US) 2014-03-13 US disclosed
US-8586581-B2 Ethynyl compounds useful for treatment of CNS disorders Hoffmann-La Roche Inc (US) 2013-11-19 US disclosed
EP-2513102-A1 ETHYNYL DERIVATIVES F. Hoffmann-La Roche AG (CH) 2012-10-24 EP disclosed
US-20110152257-A1 ETHYNYL COMPOUNDS USEFUL FOR TREATMENT OF CNS DISORDERS HOFFMANN-LA ROCHE, INC. 2011-06-23 US disclosed
WO-2011073172-A1 ETHYNYL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152257-A1 ETHYNYL COMPOUNDS USEFUL FOR TREATMENT OF CNS DISORDERS GRM5, GRIK5, GRM1 TDP1 3384/4885ALDH1A1 3951/4885GAA 1889/4885
US-20140073638-A1 ETHYNYL COMPOUNDS USEFUL FOR TREATMENT OF CNS DISORDER GRM5, GRIK5, GRM1 TDP1 3368/4885ALDH1A1 3949/4885GAA 1756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.